FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790996886> ?p ?o ?g. }

• W2790996886 endingPage "345" @default.
• W2790996886 startingPage "345" @default.
• W2790996886 abstract "345 Background: Darolutamide (ODM-201) (Daro) is an investigational oral and high-affinity androgen receptor antagonist. In preclinical studies, penetration of Daro through the blood–brain barrier (BBB) is negligible and in a retrospective safety analysis of the ARADES database for CNS-related adverse events (AEs), only 1 report of urinary incontinence was linked to Daro (Fizazi K, et al. 2015). Various clinical trials on enzalutamide (Enza) have reported CNS AEs (eg, seizure, falls, fatigue, pain). To understand the differences in CNS outcomes, we report an in vivo tissue distribution study with [ 14 C]-labelled Enza and Daro in a head-to-head study in rats by means of quantitative whole-body autoradiography (QWBA). Methods: Male rats were orally dosed with 10 mg/kg [ 14 C]Daro or [ 14 C]Enza in the same formulation, administration volume, and radioactive dose. The animals were sacrificed at each drug’s specific t max (time to reach the maximum concentration) in blood and brain and processed for QWBA. Results: At early time points [ 14 C]Daro- and [ 14 C]Enza-derived radioactivity was rapidly absorbed from the gastrointestinal tract and homogenously distributed throughout the body. By 8 h post dose, [ 14 C]Daro was significantly eliminated from almost all organs/tissues, whereas [ 14 C]Enza remained constant within the body. In contrast to [ 14 C]Daro, high and persistent radioactivity was observed in brain for [ 14 C]Enza. At t max , the brain/blood-ratio of [ 14 C]Enza was ~0.765, while [ 14 C]Daro was about 10-fold lower at ~0.074. Conclusions: Results show that post dose, there was a 10-fold lower BBB penetration of [ 14 C]Daro compared with [ 14 C]Enza. At 8 h, [ 14 C]Daro was rapidly eliminated and almost undetectable in all tissues, including brain, in contrast to [ 14 C]Enza that remained constant. These data suggest that Daro might have a lower risk of inducing CNS-related AEs than Enza. Further clinical studies are ongoing." @default.
• W2790996886 created "2018-03-29" @default.
• W2790996886 creator A5000358944 @default.
• W2790996886 creator A5006356120 @default.
• W2790996886 creator A5031864797 @default.
• W2790996886 creator A5032344894 @default.
• W2790996886 creator A5091881925 @default.
• W2790996886 date "2018-02-20" @default.
• W2790996886 modified "2023-09-24" @default.
• W2790996886 title "Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography." @default.
• W2790996886 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.345" @default.
• W2790996886 hasPublicationYear "2018" @default.
• W2790996886 type Work @default.
• W2790996886 sameAs 2790996886 @default.
• W2790996886 citedByCount "32" @default.
• W2790996886 countsByYear W27909968862019 @default.
• W2790996886 countsByYear W27909968862020 @default.
• W2790996886 countsByYear W27909968862021 @default.
• W2790996886 countsByYear W27909968862022 @default.
• W2790996886 countsByYear W27909968862023 @default.
• W2790996886 crossrefType "journal-article" @default.
• W2790996886 hasAuthorship W2790996886A5000358944 @default.
• W2790996886 hasAuthorship W2790996886A5006356120 @default.
• W2790996886 hasAuthorship W2790996886A5031864797 @default.
• W2790996886 hasAuthorship W2790996886A5032344894 @default.
• W2790996886 hasAuthorship W2790996886A5091881925 @default.
• W2790996886 hasConcept C121608353 @default.
• W2790996886 hasConcept C126322002 @default.
• W2790996886 hasConcept C197934379 @default.
• W2790996886 hasConcept C2776551883 @default.
• W2790996886 hasConcept C2780192828 @default.
• W2790996886 hasConcept C61367390 @default.
• W2790996886 hasConcept C71924100 @default.
• W2790996886 hasConcept C98274493 @default.
• W2790996886 hasConceptScore W2790996886C121608353 @default.
• W2790996886 hasConceptScore W2790996886C126322002 @default.
• W2790996886 hasConceptScore W2790996886C197934379 @default.
• W2790996886 hasConceptScore W2790996886C2776551883 @default.
• W2790996886 hasConceptScore W2790996886C2780192828 @default.
• W2790996886 hasConceptScore W2790996886C61367390 @default.
• W2790996886 hasConceptScore W2790996886C71924100 @default.
• W2790996886 hasConceptScore W2790996886C98274493 @default.
• W2790996886 hasIssue "6_suppl" @default.
• W2790996886 hasLocation W27909968861 @default.
• W2790996886 hasOpenAccess W2790996886 @default.
• W2790996886 hasPrimaryLocation W27909968861 @default.
• W2790996886 hasRelatedWork W1999742630 @default.
• W2790996886 hasRelatedWork W2594525893 @default.
• W2790996886 hasRelatedWork W2779373410 @default.
• W2790996886 hasRelatedWork W2956249214 @default.
• W2790996886 hasRelatedWork W3185685841 @default.
• W2790996886 hasRelatedWork W4223454845 @default.
• W2790996886 hasRelatedWork W4226078155 @default.
• W2790996886 hasRelatedWork W4298139082 @default.
• W2790996886 hasRelatedWork W4319984461 @default.
• W2790996886 hasRelatedWork W4381550549 @default.
• W2790996886 hasVolume "36" @default.
• W2790996886 isParatext "false" @default.
• W2790996886 isRetracted "false" @default.
• W2790996886 magId "2790996886" @default.
• W2790996886 workType "article" @default.